PMID- 34719392
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211105
IS  - 2056-5909 (Print)
IS  - 2056-5909 (Electronic)
IS  - 2056-5909 (Linking)
VI  - 27
IP  - 1
DP  - 2021 Nov 1
TI  - Real-world evidence on the strategy of olmesartan-based triple single-pill 
      combination in Korean hypertensive patients: a prospective, multicenter, 
      observational study (RESOLVE-PRO).
PG  - 21
LID - 10.1186/s40885-021-00177-z [doi]
LID - 21
AB  - BACKGROUND: In this prospective, multicenter, non-comparative observational 
      study, the effectiveness and safety of the triple single-pill combination (SPC) 
      of olmesartan/amlodipine/hydrochlorothiazide (OM/AML/HCTZ) were evaluated in a 
      real clinical practice setting in Korean patients with essential hypertension. 
      METHODS: A total of 3752 patients were enrolled and followed for 12 months after 
      administration of OM/AML/HCTZ. Primary endpoint was change from baseline to month 
      6 in the mean systolic blood pressure (SBP). Secondary endpoints included changes 
      from baseline in the mean SBP at month 3, 9, 12 and the mean diastolic blood 
      pressure (DBP) at month 3, 6, 9, 12; changes in the mean SBP/DBP according to age 
      and underlying risk factors; and blood pressure control rate (%) at different 
      time points. Adherence to and satisfaction with OM/AML/HCTZ treatment among 
      patients and physicians were assessed by medication possession ratio (MPR) and 
      numeric rating scale, respectively, as exploratory endpoints. Safety was 
      evaluated by the incidence and severity of adverse events (AEs) as well as the 
      discontinuation rate due to AEs. RESULTS: OM/AML/HCTZ administration led to 
      significant reductions in the mean SBP/DBP by 11.5/6.6, 12.3/7.0, 12.3/7.2, and 
      12.8/7.4 mmHg from baseline to month 3, 6, 9 and 12, respectively (P < 0.0001). 
      The BP reductions were maintained throughout the 1-year observation period in all 
      patients with different age groups and risk factors (diabetes mellitus, 
      cardiovascular disease, and renal disease). The BP control rate (%) of 
      < 140/90 mmHg was 65.9, 67.9, 68.9, and 70.6% at month 3, 6, 9, and 12, 
      respectively. The mean MPR during the observation period was 0.96. The safety 
      results were consistent with the previously reported safety profile of 
      OM/AML/HCTZ. CONCLUSIONS: Treatment with the triple SPC of OM/AML/HCTZ 
      demonstrated significant effectiveness in reducing SBP/DBP and achieving target 
      BP control with high adherence over the 1-year observation period in Korean 
      hypertensive patients and was well-tolerated. TRIAL REGISTRATION: CRIS, 
      KCT0002196 , Registered 3 May 2016.
CI  - (c) 2021. The Author(s).
FAU - Sohn, Il Suk
AU  - Sohn IS
AUID- ORCID: 0000-0001-8004-5185
AD  - Department of Internal Medicine, Division of Cardiology, Kyung Hee University 
      Hospital at Gangdong, Seoul, Republic of Korea.
FAU - Ihm, Sang-Hyun
AU  - Ihm SH
AUID- ORCID: 0000-0001-5017-5421
AD  - Department of Internal Medicine, Division of Cardiology, Bucheon St. Mary's 
      Hospital, College of Medicine, The Catholic University of Korea, Bucheon, 
      Republic of Korea.
FAU - Kim, Gee Hee
AU  - Kim GH
AUID- ORCID: 0000-0002-0279-7370
AD  - Department of Internal Medicine, Division of Cardiology, St. Vincent's Hospital, 
      Suwon, Republic of Korea.
FAU - Park, Sang Min
AU  - Park SM
AUID- ORCID: 0000-0001-6521-303X
AD  - Department of Cardiology, Nowon Eulji Medical Center, Eulji University, Seoul, 
      Republic of Korea.
FAU - Hong, Bum-Kee
AU  - Hong BK
AUID- ORCID: 0000-0002-6456-0184
AD  - Division of Cardiology, Heart Center, Gangnam Severance Hospital, Yonsei 
      University College of Medicine, Seoul, Republic of Korea.
FAU - Lee, Chang Hoon
AU  - Lee CH
AUID- ORCID: 0000-0002-1622-272X
AD  - Department of Internal Medicine, Division of Cardiology, Veterans Health Service 
      Medical Center, Seoul, Republic of Korea.
FAU - Lee, Sang Hyun
AU  - Lee SH
AUID- ORCID: 0000-0001-7196-2643
AD  - Department of Internal Medicine, Division of Cardiology, Pusan National 
      University Yangsan Hospital, Yangsan, Republic of Korea.
FAU - Chang, Dae-Il
AU  - Chang DI
AUID- ORCID: 0000-0001-7638-5830
AD  - Department of Neurology, Kyung Hee University Hospital, Seoul, Republic of Korea.
FAU - Joo, Sung-Pil
AU  - Joo SP
AUID- ORCID: 0000-0002-4983-0174
AD  - Department of Neurosurgery, Chonnam National University Hospital, Chonnam 
      National University Medical School, Gwangju, Republic of Korea.
FAU - Lee, Sang-Chan
AU  - Lee SC
AUID- ORCID: 0000-0001-9190-5267
AD  - Department of Neurology, Dong-Eui Hospital, Busan, Republic of Korea.
FAU - Lee, Yong-Ho
AU  - Lee YH
AUID- ORCID: 0000-0002-6219-4942
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Jeon, Dong Woon
AU  - Jeon DW
AUID- ORCID: 0000-0001-7409-4378
AD  - Department of Internal Medicine, Division of Cardiology, National Health 
      Insurance Service Ilsan Hospital, Goyang, Republic of Korea.
FAU - Jung, Kyung Tae
AU  - Jung KT
AUID- ORCID: 0000-0002-4295-7092
AD  - Department of Internal Medicine, Division of Cardiology, Eulji University 
      Hospital, Daejeon, Republic of Korea.
FAU - Rhee, Si Jae
AU  - Rhee SJ
AUID- ORCID: 0000-0003-3117-8963
AD  - Medical Affairs Department, Daiichi Sankyo Korea Co., Ltd., Seoul, Republic of 
      Korea.
FAU - Cho, Yoon-Jin
AU  - Cho YJ
AUID- ORCID: 0000-0003-0347-4773
AD  - Medical Affairs Department, Daiichi Sankyo Korea Co., Ltd., Seoul, Republic of 
      Korea.
FAU - Kim, Chong-Jin
AU  - Kim CJ
AUID- ORCID: 0000-0003-3922-7846
AD  - Department of Cardiology, CHA Gangnam Medical Center, CHA University School of 
      Medicine, Seoul, South Korea. chongjinkim@naver.com.
CN  - Investigators
LA  - eng
PT  - Journal Article
DEP - 20211101
PL  - England
TA  - Clin Hypertens
JT  - Clinical hypertension
JID - 101669508
PMC - PMC8559412
OTO - NOTNLM
OT  - Amlodipine
OT  - Hydrochlorothiazide
OT  - Hypertension
OT  - Korea
OT  - Observational study
OT  - Olmesartan
OT  - Real-world
OT  - Single-pill combination
COIS- All authors received research funds from Daiichi Sankyo Korea Co., Ltd. SJR and 
      YJC are full-time employees of Daiichi Sankyo Korea Co., Ltd. There are no 
      further conflicts of interests to declare.
FIR - Kim, Yun Sung
IR  - Kim YS
FIR - Woo, Seong-Ill
IR  - Woo SI
FIR - Lee, Kyounghoon
IR  - Lee K
FIR - Heo, Jung Ho
IR  - Heo JH
FIR - Park, Sang-Ho
IR  - Park SH
FIR - Choi, Euy Jin
IR  - Choi EJ
FIR - Hwang, Sun Ho
IR  - Hwang SH
FIR - Chung, Yonh-Gu
IR  - Chung YG
FIR - Youn, Young Jin
IR  - Youn YJ
FIR - Im, Eul-Soon
IR  - Im ES
FIR - Baik, Jong Sam
IR  - Baik JS
FIR - Choi, Nack-Cheon
IR  - Choi NC
FIR - Lee, Jin Bae
IR  - Lee JB
FIR - Ryu, Kyu-Hyung
IR  - Ryu KH
FIR - Jang, Ji-Yong
IR  - Jang JY
FIR - Park, Sung-Ji
IR  - Park SJ
FIR - Shin, Dong-Ick
IR  - Shin DI
FIR - Na, Jin Oh
IR  - Na JO
FIR - Chung, Yun Jae
IR  - Chung YJ
FIR - Kim, Su Hyun
IR  - Kim SH
FIR - Lee, Jong-Young
IR  - Lee JY
FIR - Oh, Yoon-Sang
IR  - Oh YS
FIR - Choi, Jong Hwan
IR  - Choi JH
FIR - Seo, Hye Sun
IR  - Seo HS
FIR - Kwon, Su Kyoung
IR  - Kwon SK
FIR - Kim, Hyung-Jun
IR  - Kim HJ
FIR - Park, Jin-Sun
IR  - Park JS
FIR - Park, Kyoung-Ha
IR  - Park KH
FIR - Lee, Kyoung-Soo
IR  - Lee KS
FIR - Chung, Sung Chang
IR  - Chung SC
FIR - Cho, Han-Jin
IR  - Cho HJ
FIR - Lee, Chang-Min
IR  - Lee CM
FIR - Kim, Sung-Rae
IR  - Kim SR
FIR - Kim, Jinkwon
IR  - Kim J
FIR - Oh, Hyeong-Gyun
IR  - Oh HG
FIR - Park, Ik Seong
IR  - Park IS
FIR - Chung, Pil-Wook
IR  - Chung PW
FIR - Cho, Sung-Rae
IR  - Cho SR
FIR - Kang, Hyun-Seung
IR  - Kang HS
FIR - Lee, Seung Jin
IR  - Lee SJ
FIR - Park, Kyungil
IR  - Park K
FIR - Lee, Si Won
IR  - Lee SW
FIR - Son, Jang-Won
IR  - Son JW
FIR - Kim, Soo Kyoung
IR  - Kim SK
FIR - Chung, Joong-Hwa
IR  - Chung JH
FIR - Byon, Jin-Soo
IR  - Byon JS
FIR - Lim, Hong Euy
IR  - Lim HE
FIR - Kim, Bum-Tae
IR  - Kim BT
FIR - Choi, Yu Jeong
IR  - Choi YJ
FIR - Ann, Soe Hee
IR  - Ann SH
FIR - Sung, Sang Min
IR  - Sung SM
FIR - Lee, Jun-Hee
IR  - Lee JH
EDAT- 2021/11/02 06:00
MHDA- 2021/11/02 06:01
PMCR- 2021/11/01
CRDT- 2021/11/01 05:25
PHST- 2021/02/17 00:00 [received]
PHST- 2021/08/22 00:00 [accepted]
PHST- 2021/11/01 05:25 [entrez]
PHST- 2021/11/02 06:00 [pubmed]
PHST- 2021/11/02 06:01 [medline]
PHST- 2021/11/01 00:00 [pmc-release]
AID - 10.1186/s40885-021-00177-z [pii]
AID - 177 [pii]
AID - 10.1186/s40885-021-00177-z [doi]
PST - epublish
SO  - Clin Hypertens. 2021 Nov 1;27(1):21. doi: 10.1186/s40885-021-00177-z.